Drug Profile
CT 1530
Alternative Names: CT-1530Latest Information Update: 13 Jan 2020
Price :
$50
*
At a glance
- Originator Xilintai Pharmaceutical
- Developer Centaurus Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
Most Recent Events
- 13 Jan 2020 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater) in China (unspecified route)
- 13 Jan 2020 Discontinued - Phase-I/II for Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in China (unspecified route)
- 13 Jan 2020 Discontinued - Phase-I/II for Waldenstrom's macroglobulinaemia (Monotherapy, Second-line therapy or greater) in China (unspecified route)